Crespine Gel® Plus
The same trusted hyaluronic acid implant as Crespine Gel, enhanced with prilocaine for a more comfortable single-injection experience - patented in Europe and the USA as the first HA-Prilocaine complex of its kind.
What's in each 1 ml
| Sodium hyaluronate, cross-linked | 14.0 mg |
|---|---|
| Sodium hyaluronate | 1.0 mg |
| Prilocaine HCl | 3.0 mg |
Certified under the essential requirements of Annex I of Council Directive 93/42/EEC. The HA-Prilocaine complex is patent-registered to BioPolymer GmbH with the EUIPO (No. 009258385) until 2030. Manufactured by BioPolymer GmbH & Co KG, Dümmer, Germany.
Triple functionality in one injection
Crespine Gel Plus integrates prilocaine, a local anesthetic, together with cross-linked and non-cross-linked hyaluronic acid in a single HA-Prilocaine complex - the first product of its kind registered worldwide as an intra-articular injection device. The result is the same joint-cushioning, pain-reducing action as Crespine Gel, with added comfort during administration.
Why a single injection
| Single injection |
|---|
| One clinic visit |
| Reduced risk of infection |
| Cost effective |
| Better patient compliance |
15 years of evidence-based clinical use
Patients report meaningful reductions in pain, stiffness and difficulty performing physical activities, improving from the first month, peaking around month 5, and remaining notable through month 9.
- One single injection effective for approximately 9 months.
- Ready-to-use preparation, injected directly into the osteoarthritic joint space at the clinic within minutes.
- Patented technology registered in both Europe and the USA.
Who Crespine Gel Plus is intended for
- Patients suffering from osteoarthritis pain, particularly mild-to-moderate cases.
- Patients who cannot tolerate long-term use of, or who suffer allergic reactions to, NSAIDs or other pain-relief medications.
- Patients seeking a site-specific, local treatment with minimal chair time.